📊 BETRF Key Takeaways
Investment Thesis
BetterLife Pharma is a pre-revenue pharmaceutical company in severe financial distress with minimal cash generation and unsustainable burn rate. With only $2.9K in revenue against $4.0M in operating losses and $3.6M negative free cash flow, the company faces imminent liquidity crisis given its $406.9K cash position and 0.15x current ratio.
BETRF Strengths
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Positive stockholders equity of $3.4M provides some balance sheet cushion
- Operating as a pharmaceutical company in high-value sector with potential for future value creation if pipeline succeeds
BETRF Risks
- Critically low liquidity with current ratio of 0.15x and only $406.9K cash against substantial operating burn
- Severe revenue deficit with $2.9K revenue insufficient to cover any operational costs, indicating pre-commercialization stage
- Unsustainable cash burn of $3.6M annually will deplete remaining cash reserves in approximately 1.4 months at current run rate
- Extreme negative margins (operating margin -138191%, net margin -20579%) with no path to profitability visible
- Stale financial data from October 2021 raises uncertainty about current financial position and runway
- Zero insider purchases in last 90 days suggests lack of management confidence
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway to assess solvency timeline
- Revenue growth from pharmaceutical pipeline advancement or partnerships
- Capital raise announcements or debt financing to extend operational runway
- Clinical trial progress and regulatory milestones for drug candidates
- Operating expense reduction initiatives or restructuring plans
BETRF Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BETRF Profitability Ratios
BETRF vs Healthcare Sector
How BetterLife Pharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BETRF Balance Sheet & Liquidity
BETRF 5-Year Financial Trend
5-Year Trend Summary: BetterLife Pharma Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.10 indicates the company is currently unprofitable.
BETRF Growth Metrics (YoY)
BETRF Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2019 | $5.0M | -$3.5K | N/A |
| Q3 2018 | $5.0M | $204.6K | $0.00 |
| Q1 2018 | $5.0M | -$259.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BETRF Capital Allocation
BETRF SEC Filings
Access official SEC EDGAR filings for BetterLife Pharma Inc. (CIK: 0001464165)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BETRF
What is the AI rating for BETRF?
BetterLife Pharma Inc. (BETRF) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BETRF's key strengths?
Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk. Positive stockholders equity of $3.4M provides some balance sheet cushion.
What are the risks of investing in BETRF?
Critically low liquidity with current ratio of 0.15x and only $406.9K cash against substantial operating burn. Severe revenue deficit with $2.9K revenue insufficient to cover any operational costs, indicating pre-commercialization stage.
What is BETRF's revenue and growth?
BetterLife Pharma Inc. reported revenue of $2.9K.
Does BETRF pay dividends?
BetterLife Pharma Inc. does not currently pay dividends.
Where can I find BETRF SEC filings?
Official SEC filings for BetterLife Pharma Inc. (CIK: 0001464165) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BETRF's EPS?
BetterLife Pharma Inc. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.